Stem Cell Clinic

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

By Embryonic Stem Cells

SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E (“IgE”), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria (“CSU”).

Follow this link:
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

Best Probiotic for Bloating and Gas 2025 – Top Probiotic Supplements for Gut Health from YourBiology

By Embryonic Stem Cells

GLASGOW, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- Struggling with constant bloating, gas, or an upset stomach? You’re not alone. Digestive discomfort can affect anyone, but the good news is that the right probiotic can help restore balance to your gut and provide much-needed relief.

Original post:
Best Probiotic for Bloating and Gas 2025 - Top Probiotic Supplements for Gut Health from YourBiology

Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women…

By Embryonic Stem Cells

JERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman’s oral presentation at the 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Congress in Rome entitled “EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY.”

Read more from the original source:
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women...

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

By Embryonic Stem Cells

Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans

See the rest here:
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

Parexel appoints Charlotte Moser, MD, PhD, MBA as Chief Medical Officer

By Embryonic Stem Cells

Veteran Oncologist and Clinical Development expert to lead global medical strategy supporting patient-focused drug development and delivery Veteran Oncologist and Clinical Development expert to lead global medical strategy supporting patient-focused drug development and delivery

Read more from the original source:
Parexel appoints Charlotte Moser, MD, PhD, MBA as Chief Medical Officer

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of…

By Embryonic Stem Cells

PALO ALTO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it has received approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s acute treatment of migraine with or without aura in Canada.

Read the original post:
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of...

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large…

By Embryonic Stem Cells

SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 (formerly IMPT-314) for the treatment of adult patients with relapsed and/or refractory large B-cell lymphoma after two or more prior lines of therapy. LYL314 is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19?targeted CAR T-cell therapies for the treatment of aggressive large B-cell lymphoma (LBCL).

More:
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large...

→←